Recent Approval for Ublituximab
TG's first-in- class lymphoma med ukoniq was pulled from approval by the FDA last November, but now TG has won another approval. TG's anti-CD20 treatment, Briumvi, will be available beginning in the first quarter of 2023.
TG Therapeutics Inc. Recently won approval for its ublituximab drug